Left atrial appendage closure: a percutaneous transcatheter approach for stroke prevention in atrial fibrillation
Open Access
- 31 October 2011
- journal article
- review article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 33 (6), 698-704
- https://doi.org/10.1093/eurheartj/ehr393
Abstract
Atrial fibrillation is a frequent cause of stroke; in the elderly, more than 20% of strokes are attributed to this common arrhythmia. Anticoagulation with warfarin reduces the risk of stroke by ∼60%; however, a large proportion of patients with atrial fibrillation do not receive this treatment because of relative/absolute contraindications. Moreover, patients often discontinue warfarin for a variety of reasons and chronic warfarin administration rates remain suboptimal. Although the compliance with anticoagulation may improve with novel anticoagulants and bleeding risk can be somewhat reduced when compared with warfarin, there is still a progressive increase in bleeding complications over time. Accordingly, new approaches for stroke prevention in these patients are being explored and tested. In transoesophageal echocardiographic (TEE) studies, more than 90% of thrombi were found in the left atrial appendage (LAA) in non-valvular atrial fibrillation, and transcatheter LAA closure is developed and examined as a novel approach to reduce the risk of stroke in these patients. The PROTECT-AF study provides first evidence from a randomized clinical trial that a strategy of LAA occlusion using the Watchman device can be non-inferior to anticoagulation with warfarin for a combined endpoint in patients with non-valvular atrial fibrillation (mean CHADS2 score 1.8). In successfully occluded patients fulfilling TEE criteria (86%), warfarin was stopped after 45 days, followed by aspirin and clopidogrel for 6 months after randomization and subsequently aspirin. The PREVAIL trial is further evaluating this concept. Limited data are available for another LAA occlusion system, the Amplatzer Cardiac Plug (ACP) device, for which the ACP trial has been initiated. Left atrial appendage occlusion needs to be performed with meticulous care by experienced operators because periprocedural complications such as pericardial effusion or stroke have been documented. With increased operator experience and technical improvements of the device, these complications can be minimized.Keywords
This publication has 34 references indexed in Scilit:
- Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial FibrillationCirculation, 2011
- The Incidence and Long-Term Clinical Outcome of Iatrogenic Atrial Septal Defects Secondary to Transseptal Catheterization With a 12F Transseptal SheathCirculation: Arrhythmia and Electrophysiology, 2011
- Heart Disease and Stroke Statistics—2011 UpdateCirculation, 2011
- Left atrial appendage closure with amplatzer cardiac plug in atrial fibrillation: Initial european experienceCatheterization and Cardiovascular Interventions, 2010
- Left Atrial Appendage Studied by Computed Tomography to Help Planning for Appendage Closure Device PlacementJournal of Cardiovascular Electrophysiology, 2010
- Persistent Use of Secondary Preventive Drugs Declines Rapidly During the First 2 Years After StrokeStroke, 2010
- Percutaneous Left Atrial Appendage Occlusion for Patients in Atrial Fibrillation Suboptimal for Warfarin Therapy: 5-Year Results of the PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) StudyJACC: Cardiovascular Interventions, 2009
- Stroke Severity in Atrial FibrillationStroke, 1996
- Morphology of the left atrial appendageThe Anatomical Record, 1995
- Assessment of left atrial appendage function by biplane transesophageal echocardiography in patients with nonrheumatic atrial fibrillation: Identification of a subgroup of patients at increased embolic riskJournal of the American College of Cardiology, 1994